Nutriflex Lipid 32/64/40 Perifer (Valine, Alanine, Arginine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, Threonin)

Nutriflex Lipid 32/64/40 Perifer provides parenteral lipid nutrition and is used in clinical situations that require intravenous caloric supplementation.

• Critical illness: supplies essential fatty acids and calories when oral intake is not possible.
• Post‑operative recovery: aids in wound healing and energy provision after major surgery.
• Long‑term parenteral nutrition: maintains nutritional status for patients on extended home or hospital‑based PN.
• Burn injury: delivers high‑energy lipids to support the increased metabolic demand of severe burns.
• Gastrointestinal failure: offers an alternative energy source when the gut cannot absorb nutrients.

• The emulsion delivers a balanced mixture of long‑chain triglycerides, medium‑chain triglycerides, phospholipids and essential fatty acids directly into the bloodstream. These lipids are hydrolyzed by lipoprotein lipase, providing free fatty acids that serve as an efficient energy substrate and as precursors for cell membrane synthesis, while also supporting the synthesis of eicosanoids and other signaling molecules.

Adverse reactions may occur with any parenteral lipid product and should be monitored during therapy.

Common Side Effects

• Hypertriglyceridaemia: elevated blood triglyceride levels.
• Fever or chills: transient temperature rise during infusion.
• Mild infusion site erythema: redness at the catheter site.
• Headache: occasional mild headache during or after infusion.
• Nausea: mild gastrointestinal discomfort.
• Electrolyte shift: minor changes in serum electrolytes.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Fat overload syndrome: hepatic dysfunction from excessive lipid administration.
• Pulmonary embolism: lipid droplets entering the pulmonary circulation.
• Sepsis: infection related to the catheter or infusion set.
• Coagulopathy: impaired clotting due to lipid‑induced platelet dysfunction.
• Acute respiratory distress syndrome (ARDS): severe lung injury linked to lipid infusion.

When prescribing Nutriflex Lipid 32/64/40 Perifer, clinicians should consider patient‑specific factors and monitor relevant parameters.

• Assess lipid tolerance: evaluate baseline triglyceride levels before initiation.
• Monitor liver function: watch for signs of hepatic steatosis during prolonged use.
• Check for allergies: verify no known hypersensitivity to egg phospholipids or soy oil.
• Observe infusion site: inspect regularly for signs of phlebitis or infection.
• Adjust dosage in renal or hepatic impairment: modify infusion rates as clinically indicated.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Nutriflex Lipid 32/64/40 Perifer may interact with other therapies that influence lipid metabolism or coagulation.

Major Interactions (Avoid)

• Propofol infusion: concurrent use can markedly increase serum triglycerides.
• High‑dose heparin: may potentiate hypertriglyceridaemia.
• Lipid‑soluble vitamins in excess: risk of toxicity when combined with lipid emulsions.

Moderate Interactions (Monitor Closely)

• Warfarin: lipid load can affect INR stability.
• Antiretroviral therapy (protease inhibitors): may exacerbate dyslipidaemia.
• Chemotherapeutic agents: monitor hepatic function as both can stress liver metabolism.